{"id":1020,"date":"2017-08-24T02:33:56","date_gmt":"2017-08-24T02:33:56","guid":{"rendered":"https:\/\/blogs.bmj.com\/jmg\/?p=1020"},"modified":"2026-02-24T21:01:06","modified_gmt":"2026-02-24T21:01:06","slug":"fabry-disease-characterisation-of-the-plasma-proteome-pre-and-post-enzyme-replacement-therapy","status":"publish","type":"post","link":"https:\/\/blogs.bmj.com\/jmg\/2017\/08\/24\/fabry-disease-characterisation-of-the-plasma-proteome-pre-and-post-enzyme-replacement-therapy\/","title":{"rendered":"Fabry disease: characterisation of the plasma proteome pre- and post-enzyme replacement therapy (Contributed by Dr. Beom Hee Lee)"},"content":{"rendered":"<p>Fabry disease (FD) is characterized by the progressive accumulation of globotriaosylceramide (Gb3). Enzyme replacement therapy (ERT) clears this accumulation. We analyzed plasma proteome profiles before and after ERT to characterize its molecular pathology. After ERT, the levels of proteins involved in inflammation, oxidative and ischemic injury, or complement activation were reduced significantly. In particular, we found out that inactivated complement C3b (iC3b) was significantly elevated in pre-ERT FD plasma and it gradually decreased along ERT, comparable to the changes of Gb3.Our study indicates that C3-mediated complement activation might be altered in FD and ERT might promote its stabilization. (<a href=\"http:\/\/jmg.bmj.com\/content\/early\/2017\/08\/23\/jmedgenet-2017-104704\">http:\/\/jmg.bmj.com\/content\/early\/2017\/08\/23\/jmedgenet-2017-104704<\/a> )<\/p>\n<p><a href=\"https:\/\/blogs.bmj.com\/jmg\/files\/2017\/08\/8232.jpg\"><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-1021\" src=\"https:\/\/blogs.bmj.com\/jmg\/files\/2017\/08\/8232-222x300.jpg\" alt=\"\" width=\"222\" height=\"300\" srcset=\"https:\/\/blogs.bmj.com\/jmg\/files\/2017\/08\/8232-222x300.jpg 222w, https:\/\/blogs.bmj.com\/jmg\/files\/2017\/08\/8232-768x1039.jpg 768w, https:\/\/blogs.bmj.com\/jmg\/files\/2017\/08\/8232-757x1024.jpg 757w, https:\/\/blogs.bmj.com\/jmg\/files\/2017\/08\/8232-300x406.jpg 300w\" sizes=\"auto, (max-width: 222px) 100vw, 222px\" \/><\/a><!--TrendMD v2.4.8--><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Fabry disease (FD) is characterized by the progressive accumulation of globotriaosylceramide (Gb3). Enzyme replacement therapy (ERT) clears this accumulation. We analyzed plasma proteome profiles before and after ERT to characterize its molecular pathology. After ERT, the levels of proteins involved in inflammation, oxidative and ischemic injury, or complement activation were reduced significantly. In particular, we [&#8230;]<\/p>\n<p><a class=\"btn btn-secondary understrap-read-more-link\" href=\"https:\/\/blogs.bmj.com\/jmg\/2017\/08\/24\/fabry-disease-characterisation-of-the-plasma-proteome-pre-and-post-enzyme-replacement-therapy\/\">Read More&#8230;<\/a><\/p>\n","protected":false},"author":123,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-1020","post","type-post","status-publish","format-standard","hentry","category-uncategorized"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Fabry disease: characterisation of the plasma proteome pre- and post-enzyme replacement therapy (Contributed by Dr. Beom Hee Lee) - JMG Contact blog<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/blogs.bmj.com\/jmg\/2017\/08\/24\/fabry-disease-characterisation-of-the-plasma-proteome-pre-and-post-enzyme-replacement-therapy\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Fabry disease: characterisation of the plasma proteome pre- and post-enzyme replacement therapy (Contributed by Dr. Beom Hee Lee) - JMG Contact blog\" \/>\n<meta property=\"og:description\" content=\"Fabry disease (FD) is characterized by the progressive accumulation of globotriaosylceramide (Gb3). Enzyme replacement therapy (ERT) clears this accumulation. We analyzed plasma proteome profiles before and after ERT to characterize its molecular pathology. After ERT, the levels of proteins involved in inflammation, oxidative and ischemic injury, or complement activation were reduced significantly. In particular, we [...]Read More...\" \/>\n<meta property=\"og:url\" content=\"https:\/\/blogs.bmj.com\/jmg\/2017\/08\/24\/fabry-disease-characterisation-of-the-plasma-proteome-pre-and-post-enzyme-replacement-therapy\/\" \/>\n<meta property=\"og:site_name\" content=\"JMG Contact blog\" \/>\n<meta property=\"article:published_time\" content=\"2017-08-24T02:33:56+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-02-24T21:01:06+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/blogs.bmj.com\/jmg\/files\/2017\/08\/8232.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"3500\" \/>\n\t<meta property=\"og:image:height\" content=\"4736\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"hqqu\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@HuiQiQu\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"hqqu\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/2017\\\/08\\\/24\\\/fabry-disease-characterisation-of-the-plasma-proteome-pre-and-post-enzyme-replacement-therapy\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/2017\\\/08\\\/24\\\/fabry-disease-characterisation-of-the-plasma-proteome-pre-and-post-enzyme-replacement-therapy\\\/\"},\"author\":{\"name\":\"hqqu\",\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/#\\\/schema\\\/person\\\/be0250f8d5b52412c3e7c222dabd591b\"},\"headline\":\"Fabry disease: characterisation of the plasma proteome pre- and post-enzyme replacement therapy (Contributed by Dr. Beom Hee Lee)\",\"datePublished\":\"2017-08-24T02:33:56+00:00\",\"dateModified\":\"2026-02-24T21:01:06+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/2017\\\/08\\\/24\\\/fabry-disease-characterisation-of-the-plasma-proteome-pre-and-post-enzyme-replacement-therapy\\\/\"},\"wordCount\":128,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/2017\\\/08\\\/24\\\/fabry-disease-characterisation-of-the-plasma-proteome-pre-and-post-enzyme-replacement-therapy\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/files\\\/2017\\\/08\\\/8232-222x300.jpg\",\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/2017\\\/08\\\/24\\\/fabry-disease-characterisation-of-the-plasma-proteome-pre-and-post-enzyme-replacement-therapy\\\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/2017\\\/08\\\/24\\\/fabry-disease-characterisation-of-the-plasma-proteome-pre-and-post-enzyme-replacement-therapy\\\/\",\"url\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/2017\\\/08\\\/24\\\/fabry-disease-characterisation-of-the-plasma-proteome-pre-and-post-enzyme-replacement-therapy\\\/\",\"name\":\"Fabry disease: characterisation of the plasma proteome pre- and post-enzyme replacement therapy (Contributed by Dr. Beom Hee Lee) - JMG Contact blog\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/2017\\\/08\\\/24\\\/fabry-disease-characterisation-of-the-plasma-proteome-pre-and-post-enzyme-replacement-therapy\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/2017\\\/08\\\/24\\\/fabry-disease-characterisation-of-the-plasma-proteome-pre-and-post-enzyme-replacement-therapy\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/files\\\/2017\\\/08\\\/8232-222x300.jpg\",\"datePublished\":\"2017-08-24T02:33:56+00:00\",\"dateModified\":\"2026-02-24T21:01:06+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/2017\\\/08\\\/24\\\/fabry-disease-characterisation-of-the-plasma-proteome-pre-and-post-enzyme-replacement-therapy\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/2017\\\/08\\\/24\\\/fabry-disease-characterisation-of-the-plasma-proteome-pre-and-post-enzyme-replacement-therapy\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/2017\\\/08\\\/24\\\/fabry-disease-characterisation-of-the-plasma-proteome-pre-and-post-enzyme-replacement-therapy\\\/#primaryimage\",\"url\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/files\\\/2017\\\/08\\\/8232.jpg\",\"contentUrl\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/files\\\/2017\\\/08\\\/8232.jpg\",\"width\":3500,\"height\":4736},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/2017\\\/08\\\/24\\\/fabry-disease-characterisation-of-the-plasma-proteome-pre-and-post-enzyme-replacement-therapy\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Fabry disease: characterisation of the plasma proteome pre- and post-enzyme replacement therapy (Contributed by Dr. Beom Hee Lee)\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/#website\",\"url\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/\",\"name\":\"JMG Contact blog\",\"description\":\"JMG Contact blog\",\"publisher\":{\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/#organization\",\"name\":\"JMG Contact blog\",\"url\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/files\\\/2017\\\/10\\\/blog-logo-jmg.png\",\"contentUrl\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/files\\\/2017\\\/10\\\/blog-logo-jmg.png\",\"width\":300,\"height\":34,\"caption\":\"JMG Contact blog\"},\"image\":{\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/#\\\/schema\\\/person\\\/be0250f8d5b52412c3e7c222dabd591b\",\"name\":\"hqqu\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/920bc4e81500cde88def4bfd7775029cb154e422c5460b9cf80d5c47137d6f35?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/920bc4e81500cde88def4bfd7775029cb154e422c5460b9cf80d5c47137d6f35?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/920bc4e81500cde88def4bfd7775029cb154e422c5460b9cf80d5c47137d6f35?s=96&d=mm&r=g\",\"caption\":\"hqqu\"},\"description\":\"Huiqi Qu has a background as a physician trained in internal medicine and a PhD in Experimental Medicine (Endocrinology). His research applies human genetics and multi-omics to complex and pediatric diseases, including GWAS, polygenic risk scores (PRS), single-cell transcriptomics, and integrative genomics to support precision medicine and clinical translation.\",\"sameAs\":[\"https:\\\/\\\/x.com\\\/HuiQiQu\"],\"url\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/author\\\/hqiqu\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Fabry disease: characterisation of the plasma proteome pre- and post-enzyme replacement therapy (Contributed by Dr. Beom Hee Lee) - JMG Contact blog","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/blogs.bmj.com\/jmg\/2017\/08\/24\/fabry-disease-characterisation-of-the-plasma-proteome-pre-and-post-enzyme-replacement-therapy\/","og_locale":"en_US","og_type":"article","og_title":"Fabry disease: characterisation of the plasma proteome pre- and post-enzyme replacement therapy (Contributed by Dr. Beom Hee Lee) - JMG Contact blog","og_description":"Fabry disease (FD) is characterized by the progressive accumulation of globotriaosylceramide (Gb3). Enzyme replacement therapy (ERT) clears this accumulation. We analyzed plasma proteome profiles before and after ERT to characterize its molecular pathology. After ERT, the levels of proteins involved in inflammation, oxidative and ischemic injury, or complement activation were reduced significantly. In particular, we [...]Read More...","og_url":"https:\/\/blogs.bmj.com\/jmg\/2017\/08\/24\/fabry-disease-characterisation-of-the-plasma-proteome-pre-and-post-enzyme-replacement-therapy\/","og_site_name":"JMG Contact blog","article_published_time":"2017-08-24T02:33:56+00:00","article_modified_time":"2026-02-24T21:01:06+00:00","og_image":[{"width":3500,"height":4736,"url":"https:\/\/blogs.bmj.com\/jmg\/files\/2017\/08\/8232.jpg","type":"image\/jpeg"}],"author":"hqqu","twitter_card":"summary_large_image","twitter_creator":"@HuiQiQu","twitter_misc":{"Written by":"hqqu","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/blogs.bmj.com\/jmg\/2017\/08\/24\/fabry-disease-characterisation-of-the-plasma-proteome-pre-and-post-enzyme-replacement-therapy\/#article","isPartOf":{"@id":"https:\/\/blogs.bmj.com\/jmg\/2017\/08\/24\/fabry-disease-characterisation-of-the-plasma-proteome-pre-and-post-enzyme-replacement-therapy\/"},"author":{"name":"hqqu","@id":"https:\/\/blogs.bmj.com\/jmg\/#\/schema\/person\/be0250f8d5b52412c3e7c222dabd591b"},"headline":"Fabry disease: characterisation of the plasma proteome pre- and post-enzyme replacement therapy (Contributed by Dr. Beom Hee Lee)","datePublished":"2017-08-24T02:33:56+00:00","dateModified":"2026-02-24T21:01:06+00:00","mainEntityOfPage":{"@id":"https:\/\/blogs.bmj.com\/jmg\/2017\/08\/24\/fabry-disease-characterisation-of-the-plasma-proteome-pre-and-post-enzyme-replacement-therapy\/"},"wordCount":128,"commentCount":0,"publisher":{"@id":"https:\/\/blogs.bmj.com\/jmg\/#organization"},"image":{"@id":"https:\/\/blogs.bmj.com\/jmg\/2017\/08\/24\/fabry-disease-characterisation-of-the-plasma-proteome-pre-and-post-enzyme-replacement-therapy\/#primaryimage"},"thumbnailUrl":"https:\/\/blogs.bmj.com\/jmg\/files\/2017\/08\/8232-222x300.jpg","inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/blogs.bmj.com\/jmg\/2017\/08\/24\/fabry-disease-characterisation-of-the-plasma-proteome-pre-and-post-enzyme-replacement-therapy\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/blogs.bmj.com\/jmg\/2017\/08\/24\/fabry-disease-characterisation-of-the-plasma-proteome-pre-and-post-enzyme-replacement-therapy\/","url":"https:\/\/blogs.bmj.com\/jmg\/2017\/08\/24\/fabry-disease-characterisation-of-the-plasma-proteome-pre-and-post-enzyme-replacement-therapy\/","name":"Fabry disease: characterisation of the plasma proteome pre- and post-enzyme replacement therapy (Contributed by Dr. Beom Hee Lee) - JMG Contact blog","isPartOf":{"@id":"https:\/\/blogs.bmj.com\/jmg\/#website"},"primaryImageOfPage":{"@id":"https:\/\/blogs.bmj.com\/jmg\/2017\/08\/24\/fabry-disease-characterisation-of-the-plasma-proteome-pre-and-post-enzyme-replacement-therapy\/#primaryimage"},"image":{"@id":"https:\/\/blogs.bmj.com\/jmg\/2017\/08\/24\/fabry-disease-characterisation-of-the-plasma-proteome-pre-and-post-enzyme-replacement-therapy\/#primaryimage"},"thumbnailUrl":"https:\/\/blogs.bmj.com\/jmg\/files\/2017\/08\/8232-222x300.jpg","datePublished":"2017-08-24T02:33:56+00:00","dateModified":"2026-02-24T21:01:06+00:00","breadcrumb":{"@id":"https:\/\/blogs.bmj.com\/jmg\/2017\/08\/24\/fabry-disease-characterisation-of-the-plasma-proteome-pre-and-post-enzyme-replacement-therapy\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/blogs.bmj.com\/jmg\/2017\/08\/24\/fabry-disease-characterisation-of-the-plasma-proteome-pre-and-post-enzyme-replacement-therapy\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/blogs.bmj.com\/jmg\/2017\/08\/24\/fabry-disease-characterisation-of-the-plasma-proteome-pre-and-post-enzyme-replacement-therapy\/#primaryimage","url":"https:\/\/blogs.bmj.com\/jmg\/files\/2017\/08\/8232.jpg","contentUrl":"https:\/\/blogs.bmj.com\/jmg\/files\/2017\/08\/8232.jpg","width":3500,"height":4736},{"@type":"BreadcrumbList","@id":"https:\/\/blogs.bmj.com\/jmg\/2017\/08\/24\/fabry-disease-characterisation-of-the-plasma-proteome-pre-and-post-enzyme-replacement-therapy\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/blogs.bmj.com\/jmg\/"},{"@type":"ListItem","position":2,"name":"Fabry disease: characterisation of the plasma proteome pre- and post-enzyme replacement therapy (Contributed by Dr. Beom Hee Lee)"}]},{"@type":"WebSite","@id":"https:\/\/blogs.bmj.com\/jmg\/#website","url":"https:\/\/blogs.bmj.com\/jmg\/","name":"JMG Contact blog","description":"JMG Contact blog","publisher":{"@id":"https:\/\/blogs.bmj.com\/jmg\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/blogs.bmj.com\/jmg\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/blogs.bmj.com\/jmg\/#organization","name":"JMG Contact blog","url":"https:\/\/blogs.bmj.com\/jmg\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/blogs.bmj.com\/jmg\/#\/schema\/logo\/image\/","url":"https:\/\/blogs.bmj.com\/jmg\/files\/2017\/10\/blog-logo-jmg.png","contentUrl":"https:\/\/blogs.bmj.com\/jmg\/files\/2017\/10\/blog-logo-jmg.png","width":300,"height":34,"caption":"JMG Contact blog"},"image":{"@id":"https:\/\/blogs.bmj.com\/jmg\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/blogs.bmj.com\/jmg\/#\/schema\/person\/be0250f8d5b52412c3e7c222dabd591b","name":"hqqu","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/920bc4e81500cde88def4bfd7775029cb154e422c5460b9cf80d5c47137d6f35?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/920bc4e81500cde88def4bfd7775029cb154e422c5460b9cf80d5c47137d6f35?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/920bc4e81500cde88def4bfd7775029cb154e422c5460b9cf80d5c47137d6f35?s=96&d=mm&r=g","caption":"hqqu"},"description":"Huiqi Qu has a background as a physician trained in internal medicine and a PhD in Experimental Medicine (Endocrinology). His research applies human genetics and multi-omics to complex and pediatric diseases, including GWAS, polygenic risk scores (PRS), single-cell transcriptomics, and integrative genomics to support precision medicine and clinical translation.","sameAs":["https:\/\/x.com\/HuiQiQu"],"url":"https:\/\/blogs.bmj.com\/jmg\/author\/hqiqu\/"}]}},"_links":{"self":[{"href":"https:\/\/blogs.bmj.com\/jmg\/wp-json\/wp\/v2\/posts\/1020","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/blogs.bmj.com\/jmg\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/blogs.bmj.com\/jmg\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/blogs.bmj.com\/jmg\/wp-json\/wp\/v2\/users\/123"}],"replies":[{"embeddable":true,"href":"https:\/\/blogs.bmj.com\/jmg\/wp-json\/wp\/v2\/comments?post=1020"}],"version-history":[{"count":0,"href":"https:\/\/blogs.bmj.com\/jmg\/wp-json\/wp\/v2\/posts\/1020\/revisions"}],"wp:attachment":[{"href":"https:\/\/blogs.bmj.com\/jmg\/wp-json\/wp\/v2\/media?parent=1020"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/blogs.bmj.com\/jmg\/wp-json\/wp\/v2\/categories?post=1020"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/blogs.bmj.com\/jmg\/wp-json\/wp\/v2\/tags?post=1020"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}